Watchdog sues FDA for stalling on Parkinson's drug warnings by Kyle Blankenship Tuesday, April 30, 2019 After a two-and-a-half-year wait for impulse-control warnings on six dopamine drugs, a watchdog group sued to force FDA action.
Public Citizen requests FDA black box for Amgen's Prolia by Kyle Blankenship Thursday, April 18, 2019 Despite FDA warnings that patients who stopped treatment of Amgen's Prolia had a high risk of fractures, a consumer watchdog is calling for more.
Amgen prices bone drug Evenity on par with rival Tymlos by Angus Liu Tuesday, April 16, 2019 Evenity's annual price of $21,900 is on par with that of Radius' rival med Tymlos. But its safety and clinical efficacy profile might hurt uptake.
Amgen rolls Xgeva ad in latest oncology-related TV push by Beth Snyder Bulik Monday, January 28, 2019 Amgen's Xgeva treatment for cancer-related bone problems just got a new ad campaign that includes a first-ever TV spot.
Amgen leaves celeb Blythe Danner behind in newest Prolia ad by Beth Snyder Bulik Wednesday, September 19, 2018 Amgen osteoporosis drug Prolia is working to appeal to menopausal women with a new TV ad, but it's leaving behind its celebrity spokeswoman.
Will Amgen’s migraine win and 5th Prolia nod drive enough growth? by Arlene Weintraub Tuesday, May 22, 2018 Optimistic that Amgen’s pipeline will deliver enough growth to support its $118B market cap? Think again, one Wall Street firm argues.
Amgen rolls new Prolia ads on heels of Evenity delay by Beth Snyder Bulik Thursday, August 10, 2017 Amgen debuted a Prolia TV ad with longtime spokesperson Blythe Danner, just weeks after a setback for its next-gen osteoporosis med romosozumab.
Amgen's bone drug Prolia nabs data for new use by Tracy Staton Tuesday, August 30, 2016 Amgen notched up data for a new Prolia use that could amp up the blockbuster-in-the-making, at a time when the company is bracing for biosimilar rivals to its biggest meds.
